Avinger
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 8.8m | 10.1m | 8.3m | 7.7m | 7.2m | 13.9m | 17.8m |
% growth | (4 %) | 16 % | (18 %) | (8 %) | (6 %) | 93 % | 28 % |
EBITDA | (17.3m) | (15.8m) | (16.0m) | (16.3m) | - | - | - |
% EBITDA margin | (198 %) | (156 %) | (193 %) | (214 %) | - | - | - |
Profit | (19.0m) | (17.4m) | (17.6m) | (18.3m) | (16.9m) | (12.6m) | (10.6m) |
% profit margin | (217 %) | (172 %) | (213 %) | (239 %) | (235 %) | (91 %) | (60 %) |
EV / revenue | 4.3x | 3.5x | 1.0x | 0.5x | 0.3x | 0.2x | 0.1x |
EV / EBITDA | -2.1x | -2.3x | -0.5x | -0.2x | - | - | - |
R&D budget | 5.7m | 5.9m | 4.4m | 4.5m | - | - | - |
R&D % of revenue | 65 % | 58 % | 53 % | 59 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Series A | |
N/A | $25.0m | Series B | |
$22.5m | Series C | ||
N/A | $33.0m | Series D | |
$10.5m | Debt | ||
$34.8m | Series E | ||
N/A | N/A | IPO | |
$55.0m | Post IPO Equity | ||
* | N/A | $50.0m | Post IPO Equity |
* | N/A | $31.7m | Post IPO Equity |
N/A | $18.0m | Post IPO Equity | |
N/A | $11.5m | Post IPO Equity | |
N/A | $4.5m | Post IPO Equity | |
N/A | $4.5m | Post IPO Equity | |
N/A | N/A | Post IPO Equity | |
N/A | $7.6m | Post IPO Equity | |
* | N/A | $5.3m | Post IPO Equity |
* | $15.0m | Post IPO Equity | |
* | N/A | $6.0m | Post IPO Equity |
Total Funding | AUD178m |
Related Content
Recent News about Avinger
EditAvinger, Inc. is a medical device company specializing in the treatment of vascular diseases, particularly focusing on peripheral artery disease (PAD). The company operates in the healthcare sector, targeting hospitals, clinics, and medical professionals who treat vascular conditions. Avinger's core product is its Lumivascular technology, which integrates onboard image guidance to enhance the precision and safety of vascular procedures. This technology is designed to treat small vessel diseases, especially below the knee, offering a minimally invasive solution that improves patient outcomes. The company's business model revolves around the development, manufacturing, and sale of its proprietary medical devices. Revenue is generated through the direct sale of these devices to healthcare providers and through strategic partnerships. Avinger aims to revolutionize vascular disease treatment by providing innovative, image-guided solutions that reduce the need for more invasive surgical procedures.
Keywords: Lumivascular, vascular disease, peripheral artery disease, image guidance, minimally invasive, medical devices, healthcare, precision treatment, patient outcomes, strategic partnerships.